Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04860323
Recruitment Status : Recruiting
First Posted : April 26, 2021
Last Update Posted : May 18, 2022
Sponsor:
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Prevention Trials Network
AIDS Clinical Trials Group
Information provided by (Responsible Party):
HIV Vaccine Trials Network

Brief Summary:

The purpose of this study is to learn whether having the AMP Study antibody (called VRC01) in a person's body might help their immune system control HIV better, even without HIV medication called antiretroviral therapy or ART, if they get HIV. This study will evaluate the viral and immune system responses in an Analytical Treatment Interruption (ATI), in participants who received VRC01 or placebo and got HIV while enrolled in HVTN 703/HPTN 081 (NCT02568215).

Participants in this study will stop taking their HIV medication. They will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is unable to control the HIV or they meet other ART re-start criteria as noted in section "Detailed Description". While they are not taking HIV medication, their HIV levels will be tested frequently, and their health will be monitored closely. This is called an analytical treatment interruption, or an ATI. An ATI is an experimental procedure that is only used in carefully monitored research.


Condition or disease Intervention/treatment Phase
HIV Infection Other: Analytical Treatment Interruption Not Applicable

Detailed Description:

The purpose of this study is to evaluate immunologic and virologic responses in an Analytical Treatment Interruption (ATI), in participants who received VRC01 or placebo and got HIV while enrolled in the HVTN 703/HPTN 081 Antibody-Mediated Prevention (AMP) Study (NCT02568215).

ATI begins with the cessation of ART on Schedule 1 (Monitoring ATI). Participants on Schedule 1 will attend study visits every week for the first 8 weeks and at least every 2 weeks for the next 16 weeks. After that, participants will attend study visits once a month for the next 6 months, if their body is controlling their HIV without ART. Participants on Schedule 1 for more than a year will have visits every 3 months.

For participants on Schedule 1 (Monitoring ATI), a confirmed VL ≥ 200 copies/mL will trigger transition to Schedule 2 (ATI monitoring with viremia). Participants on Schedule 2 will attend study visits every week for the first 8 weeks and at least every 2 weeks for the next 28 weeks. After that, participants will attend study visits once a month for the next 4 months, if their body is controlling their HIV without ART. Participants on Schedule 2 for more than a year will have visits every 3 months.

For participants on Schedule 1 (Monitoring ATI), any of the following non-virologic criteria will trigger re-initiation of ART and transition to Schedule 3 (Follow-up on ART): confirmed CD4+ T-cell count < 350 cells/mm3, any HIV-related syndrome, pregnancy or breastfeeding, or ART re-initiation requested by participant or if deemed medically necessary by primary HIV provider or clinical research site Investigator of Record. Participants on Schedule 3 will attend study visits every 2 weeks for the first 12 weeks, once a month for the next 16 weeks, and on 2 occasions 3 months apart for the next 24 weeks.

For participants on Schedule 2 (ATI monitoring with viremia), the following virologic criteria will trigger re-initiation of ART and transition to Schedule 3 (Follow-up on ART): viral load remains ≥ 1,000 copies/mL for ≥ 4 consecutive weeks AND viral load has not dropped 0.5 log from the previous week (Week 0 - Week 24), confirmed viral load ≥ 200 copies/mL (after Week 24). Or, the following non-virologic criteria will trigger re-initiation of ART and transition from Schedule 2 (ATI monitoring with viremia) to Schedule 3 (Follow-up on ART): confirmed CD4+ T-cell count < 350 cells/mm3, any HIV-related syndrome, pregnancy or breastfeeding, or ART re-initiation requested by participant or if deemed medically necessary by primary HIV provider or clinical research site Investigator of Record.

Study duration is potentially indefinite for participants maintaining extended viral control during ATI. Study duration for most participants is expected to be 13-18 months. The maximum anticipated duration for any participant is expected to be approximately 2 1/2 to 3 years.

Visits may include medical history review, physical exam, HIV testing, other STI testing (blood, urine, and cervical/vaginal swab collection), blood draws, pregnancy testing for participants that can become pregnant, HIV transmission risk reduction counseling, and interviews/questionnaires.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 39 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Antiretroviral Analytical Treatment Interruption (ATI) to Assess Immunologic and Virologic Responses in Participants Who Initiated ART in Early HIV Infection After Having Received VRC01 or Placebo in HVTN 703/HPTN 081
Actual Study Start Date : May 28, 2021
Estimated Primary Completion Date : August 12, 2023
Estimated Study Completion Date : August 12, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Analytical Treatment Interruption
Participants who received VRC01 or placebo and got HIV while enrolled in HVTN 703/HPTN 081 (NCT02568215).
Other: Analytical Treatment Interruption
Participants will stop taking their HIV medication and will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is not controlling their HIV or they meet other ART re-start criteria as noted in section "Detailed Description".




Primary Outcome Measures :
  1. Time from the start of ATI to meeting ART re-initiation criteria [ Time Frame: Measured through participant's last visit on Schedule 1 or 2, on average 3 months ]
    Cumulative incidence of meeting ART re-initiation criteria

  2. Percentage of participants who sustain post-treatment HIV control [ Time Frame: Measured at week 24 off ART ]
    Cumulative incidence of meeting ART re-initiation criteria

  3. Percentage of participants who experience adverse events (AEs) [ Time Frame: Measured through participant's last study visit, on average 15 months ]
    Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017

  4. Percentage of participants who experience serious adverse events (SAEs) [ Time Frame: Measured through participant's last study visit, on average 15 months ]
    Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017

  5. Percentage of participants who terminate the study early [ Time Frame: Measured through participant's last study visit, on average 15 months ]
    Tabulated by reason and HVTN 704/HPTN 085 treatment group

  6. Percentage of participants who discontinue ATI [ Time Frame: Measured through participant's last visit on Schedule 1 or 2, on average 3 months ]
    Tabulated by reason and HVTN 704/HPTN 085 treatment group


Secondary Outcome Measures :
  1. Response rate of HIV-specific CD4+ and CD8+ T-cells [ Time Frame: Measured through participant's last study visit, on average 15 months ]
    Measured by flow cytometry

  2. Magnitude of HIV-specific CD4+ and CD8+ T-cells [ Time Frame: Measured through participant's last study visit, on average 15 months ]
    Measured by flow cytometry

  3. Polyfunctionality of HIV-specific CD4+ and CD8+ T-cells [ Time Frame: Measured through participant's last study visit, on average 15 months ]
    Measured by flow cytometry

  4. Magnitude of neutralizing antibodies (nAb) responses against autologous and heterologous HIV isolates [ Time Frame: Measured through participant's last study visit, on average 15 months ]
    Measured by TZM-bl neutralization assay

  5. Non-neutralizing, FcγR-mediated antibody effector functions [ Time Frame: Measured through participant's last study visit, on average 15 months ]
    Measured by ADCC

  6. Non-neutralizing, FcγR-mediated antibody effector functions [ Time Frame: Measured through participant's last study visit, on average 15 months ]
    Measured by ADCP

  7. Non-neutralizing, FcγR-mediated antibody effector functions [ Time Frame: Measured through participant's last study visit, on average 15 months ]
    Measured by virion capture

  8. Frequency of dendritic cell activation and maturation markers [ Time Frame: Measured through participant's last study visit, on average 15 months ]
    Measured by flow cytometry or other cell phenotyping assays

  9. Frequency of T- and B-cell activation and exhaustion markers [ Time Frame: Measured through participant's last study visit, on average 15 months ]
    Measured by flow cytometry or other cell phenotyping assays

  10. Percentage of participants with viral load ≥ 200 copies/mL [ Time Frame: Measured at weeks 8, 16, and 24 for participants undergoing ATI ]
    Cumulative incidence

  11. Frequency of CD4+ T cells carrying intact and/or total pro-viral HIV DNA, replication competent virus, and/or cell-associated HIV RNA [ Time Frame: Measured through participant's last study visit, on average 15 months ]
    Measured by Intact Proviral DNA Assay (IPDA), Tat/rev Induced Limiting Dilution Assay (TILDA), assays detecting replication-competent virus-bearing cells, and/or measures of total proviral DNA. Cell-associated HIV-RNA may be quantitated as a measure of the transcriptionally active reservoir.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Estimated date of HIV-1 acquisition within 8 weeks (ie, before or after) having received an HVTN 703/HPTN 081 infusion.
  • Initiated ART within 28 weeks of HVTN 703/HPTN 081 date of HIV-1 diagnosis.
  • Receiving continuous ART for at least 1 year. ART interruptions of up to 7 days in duration and ≥ 90 days prior to enrollment are acceptable. Within- and between-class changes in ART within the previous year are acceptable.
  • If on an NNRTI, willingness and ability to switch to a PI- or INSTI-containing regimen for at least 4 weeks prior to ART interruption.
  • Willingness to interrupt ART for up to 24 weeks or up to the time of meeting ART re-initiation criteria.
  • Willingness to re-initiate ART upon meeting study ART re-initiation criteria.
  • Willingness to use barrier protection (ie, male or female condoms) for all sexual activity during ATI and until confirmation of viral suppression following ART re-initiation.
  • Willingness for CRS staff to contact primary HIV care provider to exchange information regarding HVTN 805/HPTN 093 and participant medical history.
  • Site investigator anticipates that a fully active alternative ART regimen could be constructed and would be available in the event of virologic failure on the participant's current ART regimen.
  • Access to a participating CRS and willingness to adhere to study visit schedule and to be followed for the planned duration of the study.
  • Ability and willingness to provide informed consent.
  • Assessment of understanding: volunteer demonstrates understanding of this study; completes a questionnaire prior to enrollment with verbal demonstration of understanding of all questionnaire items answered incorrectly.
  • Agrees not to enroll in another study of an investigational research agent for the duration of the participant's trial participation.

Laboratory Inclusion Values:

Immunology/Virology

  • HIV-1 infection, with reactive HIV-1 antibody and any Multispot or Geenius HIV-1/HIV-2 results, documented by the HVTN 703/HPTN 081 HIV diagnostic algorithm.
  • Plasma HIV-1 RNA ≥ 1,000 copies/mL by any assay, prior to initiating ART.
  • CD4+ T cell count ≥ 450 cells/mm3 obtained within 90 days prior to enrollment.
  • One plasma HIV-1 RNA below the lower limit of quantitation (LLOQ) of an VQA-certified or DAIDS-approved assay and collected at each of the following:

    • at screening, within 90 days prior to enrollment; and
    • greater than 9 months prior to the screening HIV-1 RNA. Note: Sites must have results from locally available assays that are approved as standard-of-care by their regional governing bodies.

Hematology

  • Hemoglobin (Hgb) ≥ 10.0 g/dL
  • Absolute neutrophil count (ANC) ≥ 750 cells/mm3
  • Platelets ≥ 100,000 cells/mm3

Chemistry

  • Alanine aminotrasferase (ALT) < 2.5 times the institutional upper limit of normal and direct bilirubin within the institutional range of normal.
  • Estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73m2

Reproductive Status

  • Volunteers capable of becoming pregnant: negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test performed at the screening visit and prior to enrollment. Persons who are NOT capable of becoming pregnant due to having reached menopause (no menses for 1 year) or having undergone total hysterectomy or bilateral oophorectomy or tubal ligation (verified by medical records) are not required to undergo pregnancy testing.
  • Reproductive status: A volunteer who is capable of becoming pregnant must agree to consistently use effective contraception (ie, IUD or hormonal) for sexual activity that could lead to pregnancy from at least 21 days prior to enrollment through confirmation of viral suppression following ART re-initiation.
  • Volunteers capable of becoming pregnant must also agree not to seek pregnancy through alternative methods, such as artificial insemination or in vitro fertilization, until after confirmation of viral suppression following ART re-initiation.

Exclusion Criteria:

  • Any plasma HIV-1 RNA ≥ LLOQ of VQA-certified or DAIDS-approved assay (LLOQ: 75, 50, 40, or 20 copies/mL) within 12 months prior to enrollment. NOTE: Two "blips" (ie, plasma HIV-1 RNA > LLOQ) < 400 copies/mL are allowed if preceded and followed by values < LLOQ and if the blips occur more than 6 months prior to enrollment. Note: Sites must have results from locally available assays that are approved as standard-of-care by their regional governing bodies.
  • History of AIDS-defining illnesses or US Centers for Disease Control (CDC) Category C events per the current list on the CDC website.
  • Autoimmune disease, including Type I diabetes mellitus (Not excluded from participation: Volunteer with mild, stable and uncomplicated autoimmune disease that does not require consistent immunosuppressive medication and that, in the judgment of the site investigator, is likely not subject to exacerbation and likely not to complicate AE assessments).
  • Immunosuppressive medications received within 6 months before enrollment (Not exclusionary: [1] corticosteroid nasal spray; [2] inhaled corticosteroids; [3] topical corticosteroids for mild, uncomplicated dermatologic condition; or [4] a single course of oral/parenteral prednisone or equivalent at doses < 60 mg/day and length of therapy < 11 days with completion at least 30 days prior to enrollment).
  • Blood products received within 120 days before planned ART interruption.
  • Investigational research agents, other than experimental vaccine(s), received within 30 days before planned ART interruption.
  • HIV or non-HIV experimental vaccine(s) received within the last 1 year. Exceptions may be made by the HVTN 805/HPTN 093 PSRT for vaccines that have subsequently undergone licensure by the FDA or by the national regulatory authority where the volunteer is enrolling. For volunteers who have received control/placebo in an experimental vaccine trial, the HVTN 805/HPTN 093 PSRT will determine eligibility on a case-by-case basis. For volunteers who have received an experimental vaccine(s) greater than 1 year ago, eligibility for enrollment will be determined by the HVTN 805/HPTN 093 PSRT on a case-by-case basis.
  • Licensed live attenuated vaccines received within 30 days before planned ART interruption (eg, measles, mumps, and rubella [MMR]; oral polio vaccine [OPV]; varicella; yellow fever; live attenuated influenza vaccine).
  • Licensed vaccines that are not live attenuated vaccines received within 14 days before planned ART interruption (eg, tetanus, pneumococcal, hepatitis A or B, influenza).
  • Receipt of any emergency-use authorized, WHO emergency use listed, licensed or registered SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine within 4 weeks before planned ART interruption.

Note: SARS-CoV-2 vaccination is not required for HVTN 805/HPTN 093 eligibility

  • Significant or unstable cardiac or cerebrovascular disease (eg, angina, congestive heart failure [CHF], recent cerebrovascular accident [CVA], or myocardial infarction [MI]).
  • Positive Hepatitis B surface antigen (HBsAg) or positive HCV RNA (Not exclusionary: positive HCV Ab with negative HCV RNA).
  • Pregnant or breastfeeding
  • Volunteers who have:

    • a SARS-CoV-2 positive test (direct viral detection, eg, viral nucleic acid or antigen detection) ≤ 14 days of enrollment, if asymptomatic OR
    • unresolved COVID-19 (ie, SARS-CoV-2 positive test AND symptoms) ≤ 14 days of enrollment (not excluded: individuals with symptoms consistent with residual sequelae of resolved COVID-19, in the clinical judgement of the investigator)
  • Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to:

    • A process that would affect the immune response;
    • A process that would require medication that affects the immune response;
    • Any contraindication to repeated blood draws, including inability to establish venous access;
    • A condition that requires active medical intervention or monitoring to avert grave danger to the volunteer's health or well-being during the study period; or
    • Any condition specifically mentioned among the exclusion criteria.
  • Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety, or a volunteer's ability to give informed consent.
  • Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, could be exacerbated by events associated with protocol participation, which include: ATI, low-level viremia, subsequent viral rebound, and ART re-initiation.
  • HIV dementia or other neurologic disease that, in the judgment of the investigator, would be a contraindication to study participation.
  • Psychiatric condition that precludes compliance with the protocol. Specifically excluded are persons with psychoses within the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years.
  • Malignancy (Not excluded from participation: Volunteer who has had malignancy excised surgically and who, in the investigator's judgment, has a reasonable assurance of sustained cure, or who is unlikely to experience recurrence of malignancy during the period of the study).
  • Current untreated or incompletely treated active tuberculosis disease or current latent tuberculosis infection (Not excluded from participation: Volunteer who has latent tuberculosis infection and is undergoing treatment, with at least one month of treatment completed)
  • Untreated or incompletely treated syphilis, gonorrhea, or chlamydia infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04860323


Locations
Layout table for location information
Botswana
Gaborone CRS Recruiting
Gaborone, Botswana
Contact: CRS Leader    267-3930335    gmasheto@bhp.org.bw   
Contact: CRS Coordinator    267-3931353    tkakhu@bhp.org.bw   
Malawi
Blantyre CRS Recruiting
Blantyre, Malawi
Contact: CRS Leader    265-1811885    sufia@jhu.edu   
Contact: CRS Coordinator    265-1811885    dhuwa@jhu.medcol.mw   
Malawi CRS Recruiting
Lilongwe, Malawi
Contact: CRS Leader    265-8614587    lchinula@unclilongwe.org   
Contact: CRS Coordinator    265-1755056    tmakuhunga@unclilongwe.org   
South Africa
CAPRISA eThekwini CRS Recruiting
Durban, South Africa
Contact: CRS Leader    27-31-260-4550    nesri.padayatchi@caprisa.org   
Contact: CRS Coordinator    27-31-6550658    Kieara.Ramtahal@caprisa.org   
Vulindlela CRS Not yet recruiting
Durban, South Africa
Contact: CRS Leader    27-31-2604208    Quarraisha.abdoolkarim@caprisa.org   
Contact: CRS Coordinator    27-33-2606861    Hilton.Humphries@caprisa.org   
Kliptown Soweto CRS Recruiting
Johannesburg, South Africa
Contact: CRS Leader    27-11-3424075    lazaruse@phru.co.za   
Contact: CRS Coordinator    27-11-9899876    masalam@phru.co.za   
Ward 21 CRS Recruiting
Johannesburg, South Africa
Contact: CRS Leader    27-11-3585414    sdelany@wrhi.ac.za   
Contact: CRS Coordinator    27-11-3585856    achikandiwa@wrhi.ac.za   
Rustenburg CRS Not yet recruiting
Rustenburg, South Africa
Contact: CRS Leader    27-87-1351575    wbrumskine@auruminstitute.org   
Contact: CRS Coordinator    27-87-1351587    tadonis@auruminstatute.org   
Zimbabwe
Milton Park CRS Not yet recruiting
Harare, Zimbabwe
Contact: CRS Leader    263-772-511104    jhakim@mweb.co.zw   
Contact: CRS Coordinator    263-24-2701356    rmahachi@uzchs-ctrc.org   
Seke South CRS Not yet recruiting
Harare, Zimbabwe
Contact: CRS Leader    263-774-430144    phunidzarira@uzchs-ctrc.org   
Contact: CRS Coorindator    263-24-2701356    tchirenda@uzchs-ctrc.org   
Spilhaus CRS Not yet recruiting
Harare, Zimbabwe
Contact: CRS Leader    263-772-335232    fmhlanga@uzchs-ctrc.org   
Contact    263-772-882704    etahuringana@uzchs-ctrc.org   
Sponsors and Collaborators
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Prevention Trials Network
AIDS Clinical Trials Group
Investigators
Layout table for investigator information
Study Chair: Shelly Karuna HVTN Core, Fred Hutch
Study Chair: Katharine Bar University of Pennsylvania
Study Chair: Simba Takuva HVTN Core, Fred Hutch
Layout table for additonal information
Responsible Party: HIV Vaccine Trials Network
ClinicalTrials.gov Identifier: NCT04860323    
Other Study ID Numbers: HVTN 805/HPTN 093
UM1AI068614 ( U.S. NIH Grant/Contract )
First Posted: April 26, 2021    Key Record Dates
Last Update Posted: May 18, 2022
Last Verified: May 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by HIV Vaccine Trials Network:
HIV
Antibody
LTNPs
ECs
VCs
Treatment interruption
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
HIV Infections
Acquired Immunodeficiency Syndrome
Blood-Borne Infections
Communicable Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases